Akanksha Sharma, MD
Neurology · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 9
Offices
9 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Hospitals listed: Banner Gateway Medical Center · California Pacific Medical Ctr-Davies Campus Hosp. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Sharma’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A169260 · Current
Licensed to practise in California · since 2020 · expires 2028-07-31 · University of Texas Southwestern Medical Center, Southwestern Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
State licence records
1 licence
- Washington MDRE.ML.60365241Physician And Surgeon Residency Limited License · since 2013 · expires 2016-07-31ExpiredNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Banner Gateway Medical CenterGilbert, AZAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of Banner Health, which runs 33 hospitals in 6 statesPatients rate it 3 of 5 · 73% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.39, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.197, Oct 2024 – Sep 2025
- California Pacific Medical Ctr-Davies Campus HospSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · No emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.187, Oct 2024 – Sep 2025
See every measure and the patient survey for Banner Gateway Medical Center
Behind the star rating — Deaths: 0 better, 6 the same, 0 worse of 6 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 8 the same, 0 worse of 8 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.39 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.197 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.15 (0.24 to 2.07) · 980 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.97 (0.63 to 1.31) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 177.12 (117.95 to 236.29) · 49 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.8 · 35 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.5 · 98 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.5 · 434 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 12 · 111 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.9 · 2,070 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.39) · 2,971 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.24 (0.04 to 0.45) · 3,484 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.18 (0.97 to 5.4) · 610 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.41 (0 to 3.01) · 317 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.68 (1.13 to 4.23) · 572 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.54 (2.79 to 18.29) · 240 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.47 (1.05 to 7.9) · 295 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.57 (0.13 to 3.02) · 294 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.62 (0 to 1.35) · 2,934 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.364 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.753 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.346 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.687 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.8 · 189 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17.7 · 117 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 5.4 · 441 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 729 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (4.5 to 7) · 865 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (8.5 to 11.8) · 865 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.5 · 78 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.2 (10.6 to 18.7) · 641 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.2) · 596 cases | No different | Jan 2024 – Dec 2024 |
What patients said (792 patients answered, 18% of those asked)
| Cleanliness | 3 |
| Nurse communication | 4 |
| Doctor communication | 2 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 4 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 78% |
| Doctors "always" communicated well | 73% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 67% |
| Doctors "always" listened carefully | 70% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 69% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 63% |
| "YES", patients would definitely recommend the hospital | 73% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
See every measure and the patient survey for California Pacific Medical Ctr-Davies Campus Hosp
Behind the star rating — Deaths: 0 better, 4 the same, 0 worse of 4 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 0 better, 4 the same, 1 worse of 5 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.187 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.02 (0 to 2.09) · 232 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.98 (0.56 to 1.4) | No different | Jul 2022 – Jun 2024 |
| Death rate for heart failure patientsComplications and deaths | 10 · 72 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.1 · 106 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.4 · 257 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 721 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.26 (0.03 to 0.49) · 2,031 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.04 to 0.45) · 2,032 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.35 (0.94 to 5.76) · 419 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.41 (0 to 3) · 211 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.84 (1.24 to 4.44) · 414 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.95 (2.91 to 20.98) · 218 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.61 (1.47 to 9.75) · 198 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.74 (0.22 to 3.26) · 52 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.32 (0 to 1.28) · 1,461 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.6 · 58 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.756 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 91 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 65.3 · 84 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -26.6 · 115 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.4 · 142 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.5 · 55 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 25 cases | None | Jul 2023 – Jun 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 312 cases | No different | Jan 2024 – Dec 2024 |
What patients said (602 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 73% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 46% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 85% |
Original Medicare doctor bills
$59,483
Medicare paid this office $59,483 for 116 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 49 | $13,747 | $113 |
| Long return visit (40+ min) | 26 | $10,050 | $150 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 27 | $9,083 | $98 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 42 | $7,523 | $139 |
| Return visit (30+ min) | 19 | $4,586 | $102 |
See all 8 services
| Long return visit (40+ min) | 49 | $13,747 | $113 |
| Long return visit (40+ min) | 26 | $10,050 | $150 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 27 | $9,083 | $98 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 42 | $7,523 | $139 |
| Return visit (30+ min) | 19 | $4,586 | $102 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 20 | $3,168 | $65 |
| Return visit (30+ min) | 29 | $3,046 | $71 |
| New patient visit (60+ min) | 11 | $1,491 | $136 |
Who their Medicare patients are
116 Original Medicare patients in 2024. Average age 74 · Women 53% · Also on Medicaid 12% · Health risk score 2.50. Sicker patients than 9 in 10 peers; the typical neurology clinician is at 1.61.
Conditions among them: High blood pressure 70% · Stroke 43% · Cancer 41% · Depression 36% · Coronary heart disease 33% · Diabetes 29% · Chronic kidney disease 23% · Dementia 22% · Atrial fibrillation 20% · Heart failure 19% · COPD 17%.
The office billed $349,808, Medicare allowed $77,316 and paid $59,483; for 638 services of 25 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 116 | 638 | 74 | 2.50 | $349,808 | $59,483 |
| 2023 | 94 | 511 | 70 | 2.25 | $272,347 | $46,834 |
| 2022 | 70 | 338 | 70 | 2.34 | $184,426 | $32,758 |
| 2021 | 91 | 508 | 73 | 2.59 | $264,592 | $46,757 |
| 2020 | 34 | 70 | 70 | 2.05 | $34,499 | $7,218 |
| 2019 | 41 | 57 | 72 | 2.59 | $15,334 | $5,334 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 7 services
| Return visit (30+ min) | 50 | $9,294 | $76 |
| Long return visit (40+ min) | 30 | $7,488 | $115 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 32 | $5,090 | $141 |
| Return visit (30+ min) | 14 | $4,640 | $108 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 15 | $4,386 | $100 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 29 | $3,911 | $66 |
| Short return visit (20+ min) | 16 | $1,313 | $55 |
2022: 6 services
| Long return visit (40+ min) | 32 | $6,774 | $119 |
| Return visit (30+ min) | 43 | $6,115 | $80 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 16 | $4,300 | $88 |
| Return visit (30+ min) | 12 | $2,485 | $113 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $2,371 | $169 |
| Short return visit (20+ min) | 16 | $925 | $49 |
2021: 8 services
| Return visit (30+ min) | 53 | $12,797 | $86 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 25 | $6,044 | $89 |
| Short return visit (20+ min) | 35 | $3,384 | $55 |
| Initial hospital care with same-day admission and discharge with straightforward or low level of medical decision making, per day at least 45 minutes | 12 | $2,961 | $114 |
| Long return visit (40+ min) | 16 | $2,570 | $122 |
| New patient visit (60+ min) | 13 | $2,105 | $162 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 18 | $1,936 | $62 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 13 | $1,801 | $113 |
2020: 1 service
| Long return visit (40+ min) | 14 | $2,198 | $100 |
2019: 2 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $1,965 | $164 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 15 | $884 | $59 |
Drugs they prescribed that Part D paid
$92,101
Pharmacies billed $92,101 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 16% of their Part D prescriptions (32 of 204) in 2024. A higher opioid share than 9 in 10 peers; the typical neurology clinician is at 0%. Long-acting opioids: 47% of their opioid prescriptions.
178 generic and 26 brand-name prescriptions · $92,101 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Briviact | 12 | $16,388 | $1,366 |
| Fentanyl | 11 | $560 | $51 |
| Lacosamide | 15 | $437 | $29 |
| Dexamethasone | 11 | $203 | $18 |
| Oxycodone | 12 | $197 | $16 |
See all 6 drugs
| Briviact | 12 | $16,388 | $1,366 |
| Fentanyl | 11 | $560 | $51 |
| Lacosamide | 15 | $437 | $29 |
| Dexamethasone | 11 | $203 | $18 |
| Oxycodone | 12 | $197 | $16 |
| Gabapentin | 11 | $103 | $9 |
Year by year
| 2024 | 204 | 37 | 16% (32) | 13% | $92,101 |
| 2023 | 139 | 36 | None | 9% | $16,278 |
| 2022 | 147 | 31 | 15% (22) | 20% | $26,267 |
| 2021 | 254 | 46 | 10% (25) | None | $130,247 |
| 2019 | 159 | 33 | None | 11% | $12,847 |
| 2018 | 127 | 28 | None | None | $8,863 |
| 2017 | 81 | 21 | 0% (0) | None | $4,991 |
| 2016 | 44 | None | 0% (0) | 32% | $8,247 |
| 2014 | 38 | 15 | None | None | $902 |
| 2013 | 40 | 14 | None | None | $13,467 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 4 drugs
| Lacosamide | 12 | $879 | $73 |
| Dexamethasone | 18 | $396 | $22 |
| Levetiracetam | 11 | $322 | $29 |
| Gabapentin | 12 | $134 | $11 |
2022: 3 drugs
| Eliquis | 13 | $11,394 | $876 |
| Gabapentin | 23 | $436 | $19 |
| Oxycodone | 11 | $351 | $32 |
2021: 6 drugs
| Vimpat | 25 | $23,210 | $928 |
| Gabapentin | 21 | $442 | $21 |
| Dexamethasone | 25 | $396 | $16 |
| Baclofen | 11 | $339 | $31 |
| Oxycodone | 12 | $339 | $28 |
| Metoclopramide | 20 | $160 | $8 |
2019: 4 drugs
| Levetiracetam | 22 | $1,002 | $46 |
| Zonisamide | 14 | $420 | $30 |
| Dexamethasone | 12 | $187 | $16 |
| Gabapentin | 18 | $173 | $10 |
2018: 1 drug
| Gabapentin | 11 | $110 | $10 |
2017: 1 drug
| Dexamethasone | 12 | $118 | $10 |
Money from drug and device companies
$327 in 2025
| 2025 | 4 | 5 | None | $327 |
| 2024 | 7 | 10 | $2,146 | $2,636 |
| 2023 | 6 | 13 | $6,025 | $7,585 |
| 2022 | 5 | 6 | None | $151 |
| 2021 | 6 | 8 | None | $222 |
| 2020 | 2 | 2 | None | $39 |
| 2019 | 1 | 1 | None | $78 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Novocure | Optune Gio | $185 | 2 payments
|
| Jazz Pharmaceuticals | Modeyso | $101 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $22 | 1 payment
|
| Eisai | Lenvima | $19 | 1 payment
|
See all 5 published payments
| Jazz Pharmaceuticals | Meals · 2025-11-18 | Modeyso | $101 |
| Novocure | Meals · 2025-11-18 | None | $149 |
| Novocure | Meals · 2025-10-30 | Optune Gio | $35 |
| Eisai | Meals · 2025-02-10 | Lenvima | $19 |
| Merck Sharp & Dohme | Meals · 2025-02-05 | Keytruda | $22 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $2,636
| Servier Pharmaceuticals | None | $2,255 | 3 payments
|
| Novocure | Optune | $241 | 2 payments
|
| Octapharma USA | Octagam Immune Globulin (Human) | $33 | 1 payment
|
| Lilly USA | Verzenio | $32 | 1 payment
|
| Novartis Pharmaceuticals | Mekinist | $30 | 1 payment
|
| Daiichi Sankyo | Enhertu | $25 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | None | $20 | 1 payment
|
2023: $7,585
| Novocure | Optune | $7,462 | 6 payments
|
| Seagen | Tukysa | $32 | 1 payment
|
| Bayer Healthcare Pharmaceuticals | Vitrakvi | $29 | 1 payment
|
| Octapharma USA | Panzyga | $26 | 1 payment
|
| Foundation Medicine | Foundationone Liquid Cdx | $20 | 1 payment
|
| Cumberland Pharmaceuticals | Sancuso | $17 | 1 payment
|
2022: $151
| Alexion Pharmaceuticals | Soliris | $52 | 2 payments
|
| CSL Behring | Hizentra | $34 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $32 | 1 payment
|
| Novocure | None | $18 | 1 payment
|
| ADC Therapeutics America | None | $15 | 1 payment
|
2021: $222
| Novocure | Optune | $71 | 1 payment
|
| Neurelis | Valtoco | $46 | 2 payments
|
| Daiichi Sankyo | Turalio | $38 | 2 payments
|
| Biogen | None | $28 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Vitrakvi | $20 | 1 payment
|
| Lilly USA | Cyramza | $18 | 1 payment
|
2020: $39
| Lilly USA | Cyramza | $23 | 1 payment
|
| Amgen | Xgeva | $15 | 1 payment
|
2019: $78
| Novocure | Oncology | $78 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Novocure GmbH · Ef-32 Trident A Pivotal Randomized, Open -Label Study of Tumor Treating Fields (Optune, 200khz) Concomitant With Radiation Therapy and Temazolomde for the Treatment of New Diagnosed Glioblastoma · 2023 | Their institution | $49,022 |
| Incyte Corporation · A Phase 2, Open-Label, Single-Arm, Multicenter Study To Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma Or Other Primary Central Nervous System Tumors Harboring Activating Fgfr1-3 Alterations (Fight-209) · 2023 | Their institution | $48,549 |
| Novocure GmbH · Ef-32 Trident A Pivotal Randomized, Open -Label Study of Tumor Treating Fields (Optune, 200khz) Concomitant With Radiation Therapy and Temazolomde for the Treatment of New Diagnosed Glioblastoma · 2024 | Their institution | $38,187 |
| Incyte Corporation · A Phase 2, Open-Label, Single-Arm, Multicenter Study To Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma Or Other Primary Central Nervous System Tumors Harboring Activating Fgfr1-3 Alterations (Fight-209) · 2024 | Their institution | $34,394 |
| Incyte Corporation · A Phase 2, Open-Label, Single-Arm, Multicenter Study To Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma Or Other Primary Central Nervous System Tumors Harboring Activating Fgfr1-3 Alterations (Fight-209) · 2025 | Their institution | $20,102 |
| Novocure GmbH · Ef-32 Trident A Pivotal Randomized, Open -Label Study of Tumor Treating Fields (Optune, 200khz) Concomitant With Radiation Therapy and Temazolomde for the Treatment of New Diagnosed Glioblastoma · 2025 | Their institution | $15,877 |
Professional record
- NPI
- 1124361712
- Licence
- AZ 54107, CA A169260, WA ML603265241, WA ML 60365241California A169260: Current · expires 2028-07-31Washington MDRE.ML.60365241: Expired
- Trained
- University of Texas Southwestern Medical School at Dallas, 2013
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Neurology (2084N0400X)
- Mailing address
- 1580 Valencia St Fl 6, San Francisco, CA, 94110
- NPI first listed
- 2013-04-01
- NPI last updated
- 2026-08-08
- NPI record certified
- 2026-08-08
This is when the NPI record was last certified, not a medical board exam.